Maryland is currently home to 2684 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 8, Baltimore, Maryland
Conditions: FSGS
Register for Updates
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
NCT06101017
Recruiting
The goal is to develop a nationwide registry to track longitudinal clinical outcomes of and store imaging data related to numerous corneal conditions. There are two main objectives including the establishment of the first nationwide corneal transplant registry in the United States to include information related to the donor tissue, recipient, surgical procedure, and long-term clinical outcomes. Ultimately, this prospective data collection will allow us to determine prognostic factors for success... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Keratoplasty Alliance International, Baltimore, Maryland
Conditions: Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: MD Medical Research, Oxon Hill, Maryland
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: Medstar Health Research Institute, Hyattsville, Maryland
Conditions: Iliofemoral; Thrombosis
Register for Updates
Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
NCT06034288
Recruiting
Purpose: Multiple formulations and brands of botulinum toxin exist on the market today. Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder. IncobotulinumtoxinA (XEOMIN®) is a similar formulation of botulinum toxin A that has similar dosing and safety profile at onabotulinumtoxinA. OnabotulinumtoxinA is the most expensive formulation on the market. Compare the efficacy of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals) to onabotulinumtoxinA (Botox®,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Overactive Bladder Syndrome
Register for Updates
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: GSK Investigational Site, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
NCT06065605
Recruiting
The purpose of this research is to collect biological samples (urine) to develop assays for immune biomarkers to possibly in the future be able to screen subjects with Fabry disease and be able to understand better progression of nephropathy in Fabry disease and predict nephropathy in Fabry disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/29/2023
Locations: Lysosomal & Rare Disorders Research & Treatment Center, Rockville, Maryland
Conditions: Fabry Disease
Register for Updates
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
NCT05123755
Recruiting
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: MedStar Health Research Institute, Inc., Hyattsville, Maryland
Conditions: Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection
Register for Updates
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
NCT05267899
Recruiting
The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors. The study is also done to learn how the study drug is taken up by your body; this is called Pharmacokinetic (PK) studies and how the study drug affects the body; this is called Pharmacodynamics (PD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Solid Tumors
Register for Updates
Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer
NCT04868214
Recruiting
The Perosphere Technologies' PoC Coagulometer measures clotting times of fresh whole blood samples. Clotting is initiated by glass surface activation and terminates on optical detection of fibrin assembly, the final step in the coagulation cascade. Since activation occurs at the top of the intrinsic pathway and detection occurs at the bottom of the final common pathway, the Perosphere Technologies' PoC Coagulometer has shown sensitivity to a broad range of drugs and reagents that affect blood cl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/25/2023
Locations: Perosphere Technologies Inc., Rockville, Maryland
Conditions: Coagulation
Register for Updates
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
NCT06058234
Recruiting
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Gender:
ALL
Ages:
All
Trial Updated:
09/21/2023
Locations: Centers for Medicare and Medicaid Services, Baltimore, Maryland
Conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Register for Updates